BridgeBio Pharma, Inc. filed a Form 8-K on August 17, 2026, disclosing that selling stockholder KKR Genetic Disorder L.P. entered into an Underwriting Agreement on August 13, 2026, to offer 5,000,000 shares of BridgeBio common stock at $78.00 per share.

Key Highlights

  • Selling Stockholder: KKR Genetic Disorder L.P. is selling all 5,000,000 shares; BridgeBio Pharma, Inc. will not receive any proceeds from the offering.
  • Offer Price: Shares priced at $78.00 per share to the public.
  • Share Count: 5,000,000 shares of common stock, par value $0.001 per share, are being offered.
  • Expected Closing: The sale of the shares is expected to be completed on August 17, 2026.
  • Underwriters: William Blair & Company, L.L.C., Goldman Sachs & Co. LLC, and KKR Capital Markets LLC are acting as representatives of the several underwriters.
  • Registration: The offering was made pursuant to a shelf registration statement on Form S-3ASR (File No. 333-297701), including a prospectus dated July 24, 2026, supplemented by a prospectus supplement dated August 13, 2026.

KKR Genetic Disorder L.P. Conducts Secondary Sale of BridgeBio Common Stock

According to the filing, BridgeBio Pharma, Inc. (NASDAQ:BBIO) entered into an Underwriting Agreement on August 13, 2026, with KKR Genetic Disorder L.P. as the selling stockholder, and William Blair & Company, L.L.C., Goldman Sachs & Co. LLC, and KKR Capital Markets LLC as representatives of the underwriters. The agreement covers the sale of 5,000,000 shares of BridgeBio common stock at a public offering price of $78.00 per share. The company disclosed that it "will not receive any of the proceeds from the sale of the Shares being offered by the Selling Stockholder."

The filing notes that BridgeBio made "certain customary representations, warranties and covenants concerning the Company and the registration statement" in the Underwriting Agreement, and agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act of 1933, as amended. The offering was made under an effective shelf registration statement on Form S-3ASR (File No. 333-297701), with a prospectus dated July 24, 2026, and a prospectus supplement dated August 13, 2026, filed on August 14, 2026.

The company also disclosed that press releases announcing the launch of the offering (dated August 13, 2026) and the pricing of the offering (dated August 14, 2026) were issued and attached as exhibits. The filing was signed by Thomas Trimarchi, President and Chief Financial Officer, on August 17, 2026. The filing states that the Form 8-K "does not constitute an offer to sell or the solicitation of an offer to buy any of the Shares."

What Was Disclosed

BridgeBio Pharma filed an 8-K disclosing a secondary offering of 5,000,000 common shares at $78.00 per share by selling stockholder KKR Genetic Disorder L.P., with the company receiving none of the proceeds and the sale expected to close August 17, 2026.